All lobbying filings

AKIN GUMP STRAUSS HAUER & FELD

Lobbying for BAMBOO HEALTH · Healthcare and prescription drug monitoring

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$70,000

What the client paid this registrant for the period.

Client based in

Kentucky

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to behavioral health services, prescription drug monitoring programs, care coordination, including for VA, Medicare and Medicaid beneficiaries, and veteran mental health; Issues related to the 988 Suicide and Crisis Lifeline; Issues related to the Great American Recovery Initiative; Issues related to the final FY26 Labor-HHS Appropriations bill (P.L. 119-75); Issues related to SUPPORT Act reauthorization (including S. 2433, H.R. 4531); Issues related to the RECONNECTIONS Act (within H.R.4531/S. 2433); Issues related to FY27 appropriations and related report language for Labor-HHS and CJS, including Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260) and Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 (H.R. 8845).

Bills named in this filing 4

S. 2433
Neonatal Care Transparency Act of 2025
H.R. 4531
BANNED in Latin America Act
H.R. 9260
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
H.R. 8845
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.